Glioblastoma: KOL Insight

  • ID: 4521357
  • Report
  • FirstWord Publishing
1 of 3

Are novel therapies set to revolutionise glioblastoma?

There has been little progress in the treatment of glioblastoma (GBM) for decades, and management of patients continues to remain challenging. Novel treatment approaches are advancing into late-stage development, but what chances do these programmes have in reaching the market?

Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 pipeline therapies targeting various aspects of the GBM disease pathophysiology

Take a tour of the report now
  • The table of contents >
  • The key business questions answered >
  • The key KOL quotes >
  • See the therapies covered >
  • Find out who the 6 EU & 6 US KOLs are >
  • Review an extract from the report -1 drug profile >
Top takeaways
  • Is Avastin’s (Roche) future in the GBM therapeutic strategy tenable? How do oncologists view bevacizumab and will the therapy continue to be a part of the treatment regimen for GBM?
  • Will Biocon’s BIOMAb EGFR reach the major US and EU markets? Phase II studies are ongoing for nimotuzumab in Cuba but how do KOLs rate its chances.
  • Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
  • Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
  • Will Merck/Pfizer’s avelumab + axitinib (Inlyta) combination find a place in recurrent GBM? What do KOLs think of GliAvAx study?
  • Can Medimmune (AZ)’s durvalumab/tremelimumab challenge BMS and Merck in the checkpoint inhibitor space? What potential do KOLs think anti-PD-1/CTLA-4 agents have in GBM?
  • How do oncologists view the DCVax-L vaccine product and what are the chances of Tocagen’s Toca 511 gene therapy reaching the market? Will these therapies have a role in GBM?
  • What questions do KOLs have regarding VBL Therapeutics’ ofranergene obadenovec (VB-111)? How do KOLs rate its chances?
  • According to KOLs, what challenges does AbbVie’s ABT-414 face? Will the EGFR inhibitor have broad application?
  • Can Astellas/Roche’s erlotinib + bevacizumab combination succeed in GBM? What do KOLs think of the the GLOBE study?
  • Will AbbVie’s PARP inhibitor have a future in GBM? What do KOLs think of AbbVie’s veliparib, AstraZeneca’s olaparib and BeiGene’s BGB-290?
  • What do KOLs think of CDK4/6 inhibitors? Will Lilly’s abemaciclib (Verzenio) reach the GBM market?
  • Will p-53 pathway be ‘druggable’ in GBM? Can ONC 201 succeed where many other have failed?
  • What challenges does DelMar’s VAL-083 face? Can the chemotherapy agent overcome the high hurdles and reach the market? What do KOLs say?
Quotes

“We don't have a drug that works in GBM, so any drug that works would be great.” US Key Opinion Leader

“Clinical trials are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ongoing at the moment.” US Key Opinion Leader

Sample of therapies covered

Marketed Therapies
  • Avastin (Roche/Genentech)
  • BIOMAb EGFR (Biocon)
  • Feron (Toray/Daiichi Sankyo)
Pipeline Therapies
  • Bavencio (avelumab; Merck Group)
  • DCVax-L (Northwest Biotherapeutics)
  • depatuxizumab mafodotin (ABT-414; AbbVie)
  • dianhydrogalactitol (VAL-083; DelMar)
  • veliparib (AbbVie)
  • flucytosine (Toca FC; Tocagen)
  • Imfinzi (durvalumab; MedImmune (AstraZeneca))
  • Inlyta (axitinib; Pfizer)
  • ITK 1 (BrightPath/FUJIFILM)
  • Keytruda (pembrolizumab; Merck & Co.)
  • ofranergene obadenovec (VB-111; VBL Therapeutics)
  • ONC 201 (Oncoceutics)
  • Opdivo (nivolumab; BMS/Ono Pharmaceutical)
  • ribociclib (Novartis)
  • Tarceva (erlotinib; Astellas/Genentech (Roche))
  • Tremelimumab (MedImmune (AstraZeneca))
  • Verzenio (abemaciclib; Eli Lilly)
  • vocimagene amiretrorepvec (Toca 511; Tocagen)
  • Yervoy (ipilimumab; BMS/Ono Pharmaceutical)
KOLs interviewed

KOLs from North America
  • Anonymous KOL, MD, Professor, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  • Glenn J Lesser, MD, Professor, Hematology & Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
  • Henry S Friedman, MD, Professor of Neurosurgery; Deputy Director, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
  • John H Sampson, MD, PhD, MBA, MHSc, Professor & Chief, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USAB5
  • Timothy F Cloughesy, MD, Professor, Director, UCLA Neuro-Oncology Program, The Ronald Reagan UCLA Medical Center, University of California Los Angeles, CA, USA
  • Tom Mikkelsen, MD, FRCPC, President and Scientific Director, Ontario Brain Institute, Toronto, ON, Canada & Co-Director, Henry Ford Health System, Henry Ford Hospital, Detroit, MI, USA
KOLs from Europe
  • Andreas F Hottinger, MD, PhD, Department of Clinical Neurosciences, University Hospital Centre of Vaud, Division of Surgical Research & Gene Therapy Centre, Vaud, Switzerland
  • Anthony J Chalmers, MD, Professor/Chair of Clinical Oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK
  • Carmen Balana, MD, PhD, Head of Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
  • Martin J van den Bent, MD, PhD, Professor, Head of the Neuro-Oncology Unit, Daniel den Hoed Cancer Centre, Erasmus University, Rotterdam, Netherlands
  • Michael Weller, MD, PhD, Professor, University Hospital Zurich, Department of Neurology, Zurich, Switzerland
  • Olivier L Chinot, MD, Professor & Head of Department, Assistance Publique Hôpitaux de Marseille, APHM, Hopital de la Timone, Marseille, France
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Executive summary

2. Research objectives

3. Research focus
3.1 GBM treatment
3.2 Other modalities

4. Marketed therapies Targeted agents/immunotherapies
4.1 Avastin (bevacizumab; Roche)
4.2 BIOMAb EGFR (nimotuzumab; Biocon Biopharmaceuticals/others)
4.3 Feron (interferon-ß-1b; Toray/Daiichi Sankyo)

5. Pipeline therapies
5.1 Overview

6. Checkpoint inhibitors
6.1 Overview
6.1.1 Opdivo/Yervoy (nivolumab/ipilimumab; Bristol-Myers Squibb/Ono Pharmaceuticals)
6.1.2 Keytruda (pembrolizumab; Merck & Co.)
6.1.3 Bavencio (avelumab; Merck Group/Pfizer)
6.1.4 Durvalumab (Imfinzi)/tremelimumab; MedImmune (AstraZeneca)

7. Vaccines/immunostimulants
7.1 Overview
7.1.1 DCVax-L (Northwest Biotherapeutics)
7.1.2 ITK-1 (peptide vaccine; BrightPath Biotherapeutics/FUJIFILM)

8. Gene therapy/antisense agents
8.1 Overview
8.1.1 Toca 511 (vocimagene amiretrorepvec; Tocagen)
8.1.2 OT-101 (trabedersen (Autotelic/Oncotelic)

9. Anti-angiogenic and vascular disrupting agents
9.1 Overview
9.1.1 Ofranergene obadenovec (VB-111; VBL Therapeutics)

10. EGFR inhibitors
10.1 Overview
10.1.1 Depatuxizumab mafodotin (ABT-414; AbbVie)
10.1.2 Tarceva (erlotinib; Astellas/ Roche)

11. PARP1/2 inhibitors
11.1 Overview
11.1.1 Veliparib (AbbVie)

12. Cell cycle CDK4/CDK6 inhibitors
12.1 Overview
12.1.1 Verzenio (abemaciclib; Lilly)

13. Other novel agents
13.1 Overview
13.1.1 ONC201 (Oncoceutics)/Frontida BioPharm

14. Chemotherapy agents
14.1 Overview
14.1.1 Dianhydrogalactitol (VAL-083; DelMar Pharmaceuticals)

15. Conclusion
15.1 Current and future treatment algorithm

16. Appendix
16.1 KOL details
16.1.1 KOLs from North America
16.1.2 KOLs from Europe
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll